Allergan: A Splitting Headache?

J.P. Morgan's Chris Schott says a sum-of-the-parts analysis shows that Allergan is “highly undervalued." Still, he says it's too early to consider a split.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.